Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEffect of the Thromboxane Prostaglandin Receptor Antagonist Terutroban on Arterial Thrombogenesis after Repeated Administration in Patients Treated for the Prevention of Ischemic Stroke
Cerebrovascular Diseases, 09/15/09
Dit Sollierc CB et al. – Terutroban has demonstrated an antithrombotic activity that is superior to aspirin and similar to clopidogrel + aspirin; it induces a significant in vivo reduction in endothelial/platelet activation.
Related Articles
Segmental arterial mediolysis: course, sequelae, prognosis, and pathologic–radiologic correlation
Cardiovascular Pathology, 11/06/09
Relevance Score: 46%
Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: A dose-response relationship independent of established cardiovascular risk factors
Rheumatology, 10/28/09
Relevance Score: 46%
Women and peripheral arterial disease
Women's Health, 10/30/09
Relevance Score: 45%
Relationship between arterial baroreflex sensitivity and exercise capacity in patients with acute myocardial infarction
Clinical Physiology and Functional Imaging, 10/28/09
Relevance Score: 45%
Pre-diabetes and arterial stiffness in uraemic patients
Nephrology Dialysis Transplantation, 10/30/09
Relevance Score: 44%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/07/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Sponsor
Article Search
Sponsor